Human Apolipoprotein A5 (ApoA5) CLIA Kit

Product specifications

CLIA Kits

Apolipoprotein A5 (ApoA5)

Human

Chemiluminescent

Quantitative

Sandwich

15.6 pg/ml - 1000 pg/ml

9.38 pg/ml

Optimal dilutions/concentrations should be determined by the end user.

96 tests

Lyophilized

CLIA

Serum, plasma and other biological fluids.

Shipped within 5-12 working days.

 Shipped at 4 °C. Upon receipt, store the kit according to the storage instruction in the kit's manual.

No

APOA5, APOAV, RAP3, apolipoprotein A5, APO A5,APO A-5,Apolipoprotein A-V

CLIA Kits ApoA5

RUO

The validity for this kit is 6 months.   This product is for research use only.   The range and sensitivity is subject to change. Please contact us for the latest product information. For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a specific range, please contact us in advance or write your request in your order comments.   Please note that our ELISA and CLIA kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may have different sequences or tertiary structures to the native protein.

Descripción

APOA5 is a critical regulator of plasma triglyceride (TG) levels, playing an essential role in lipid metabolism and cardiovascular health It is primarily synthesized in the liver and is a minor apolipoprotein component of chylomicrons and very-low-density lipoproteins (VLDL) APOA5 functions by enhancing the activity of lipoprotein lipase (LPL), which hydrolyzes triglycerides in VLDL and chylomicrons, thereby reducing plasma triglyceride levels Genetic variants in the APOA5 gene are strongly associated with hypertriglyceridemia, which is a major risk factor for cardiovascular diseases (CVD), atherosclerosis, and pancreatitis APOA5 interacts with cell surface receptors such as GPIHBP1 to facilitate LPL activity and triglyceride clearance from the bloodstream Studies have shown that reduced APOA5 expression leads to elevated triglycerides and increased risk of metabolic syndrome APOA5 also modulates lipid storage in adipose tissue, highlighting its broader role in lipid homeostasis APOA5 is being investigated as a therapeutic target for hyperlipidemia and related cardiovascular conditions, as strategies enhancing APOA5 expression or function may improve triglyceride metabolism and reduce cardiovascular risks

Related Products

Human Apolipoprotein A5 (ApoA5) CLIA Kit

Human Apolipoprotein A5 (ApoA5) Chemiluminescent Immunoassay (CLIA) Kit is a Chemiluminescent Immunoassay (CLIA) kit against Apolipoprotein A5 (ApoA5).

Ver Producto